Rahman, Masmudur M.
Bagdassarian, Eugenie
Ali, Mohamed A. M.
McFadden, Grant
Article History
Received: 29 March 2017
Accepted: 6 November 2017
First Online: 16 November 2017
Competing Interests
: G.M. is an advisor to DNAtrix, which is developing MYXV as an oncolytic virotherapeutic for human cancer.